Essex Bio-Technology Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Essex Bio-Technology.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	35.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Essex Bio-Technology no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:1061 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	1,707	275	211	339	N/A
9/30/2023	1,634	266	169	323	N/A
6/30/2023	1,561	256	127	307	N/A
3/31/2023	1,439	241	113	345	N/A
12/31/2022	1,318	225	100	383	N/A
9/30/2022	1,437	274	103	406	N/A
6/30/2022	1,556	323	106	430	N/A
3/31/2022	1,597	334	130	419	N/A
12/31/2021	1,638	346	154	409	N/A
9/30/2021	1,515	339	124	430	N/A
6/30/2021	1,392	332	94	451	N/A
3/31/2021	1,185	275	32	375	N/A
12/31/2020	978	219	-31	299	N/A
9/30/2020	1,000	221	13	253	N/A
6/30/2020	1,022	222	57	207	N/A
3/31/2020	1,151	262	57	220	N/A
12/31/2019	1,279	303	57	233	N/A
9/30/2019	1,238	282	32	213	N/A
6/30/2019	1,197	262	8	194	N/A
3/31/2019	1,187	246	53	197	N/A
12/31/2018	1,176	231	99	201	N/A
9/30/2018	1,100	210	119	207	N/A
6/30/2018	1,023	189	138	214	N/A
3/31/2018	961	178	131	204	N/A
12/31/2017	900	167	125	194	N/A
9/30/2017	874	159	N/A	166	N/A
6/30/2017	849	151	N/A	138	N/A
3/31/2017	813	144	N/A	114	N/A
12/31/2016	776	136	N/A	90	N/A
9/30/2016	740	126	N/A	63	N/A
6/30/2016	705	115	N/A	37	N/A
3/31/2016	679	110	N/A	53	N/A
12/31/2015	654	105	N/A	69	N/A
9/30/2015	627	101	N/A	75	N/A
6/30/2015	600	96	N/A	81	N/A
3/31/2015	559	86	N/A	58	N/A
12/31/2014	518	75	N/A	35	N/A
9/30/2014	466	67	N/A	43	N/A
6/30/2014	413	59	N/A	51	N/A
3/31/2014	380	57	N/A	58	N/A
12/31/2013	347	55	N/A	65	N/A
9/30/2013	326	51	N/A	54	N/A
6/30/2013	305	46	N/A	44	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 1061 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 1061 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 1061 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 1061 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 1061 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 1061 se prevé que sea elevada dentro de 3 años.

Essex Bio-Technology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Price target decreased to HK$6.00

Consensus revenue estimates fall by 18%

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Price target increased to HK$7.00

Recent updates

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

New 90-day high: HK$4.40

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

New 90-day low: HK$3.74

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

New 90-day low: HK$3.96

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Executive Director & Company Secretary recently bought HK$193k worth of stock

New 90-day low: HK$3.99

New 90-day low: HK$4.43

Essex Bio-Technology Limited Announces Management Changes

New 90-day low - HK$4.69

First half earnings released